Cargando…

Immune microenvironment composition in non‐small cell lung cancer and its association with survival

OBJECTIVES: In non‐small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In this in silico study, the immune infiltrate composition in NSCLC patients was evaluated. METHODS: Gene expression data of tumors from early NSCLC patients were obtained from Gene Exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamminga, Menno, Hiltermann, Thijo Jeroen N, Schuuring, Ed, Timens, Wim, Fehrmann, Rudolf SN, Groen, Harry JM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291326/ https://www.ncbi.nlm.nih.gov/pubmed/32547744 http://dx.doi.org/10.1002/cti2.1142

Ejemplares similares

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
por: Kerner, Gerald S. M. A., et al.
Publicado: (2013)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
por: Saber, Ali, et al.
Publicado: (2016)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
por: Saber, Ali, et al.
Publicado: (2016)

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
por: Wei, Jiacong, et al.
Publicado: (2020)

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
por: Donker, H. C., et al.
Publicado: (2023)

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC)
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
por: Kerner, Gerald SMA, et al.
Publicado: (2014)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
por: van der Wekken, A. J., et al.
Publicado: (2017)

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2020)

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2023)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era
por: Eggen, Annemarie C, et al.
Publicado: (2021)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Airflow Limitation Increases Lung Cancer Risk in Smokers: The Lifelines Cohort Study
por: Du, Yihui, et al.
Publicado: (2022)

Correspondence between primary and secondary care about patients with cancer: A qualitative mixed‐methods analysis
por: Stegmann, Mariken E., et al.
Publicado: (2018)

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands
por: Wolff, Henri B., et al.
Publicado: (2022)

(18)F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions
por: Hendriks, Anne M., et al.
Publicado: (2021)

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis
por: de Wit, Sanne, et al.
Publicado: (2018)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

Reticular basement membrane in asthma and COPD: Similar thickness, yet different composition
por: Liesker, Jeroen JW, et al.
Publicado: (2009)

Microarray amplification bias: loss of 30% differentially expressed genes due to long probe – poly(A)-tail distances
por: Boelens, Mirjam C, et al.
Publicado: (2007)

Tumor microenvironments, the immune system and cancer survival
por: Strausberg, Robert L
Publicado: (2005)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

The Immune Endocannabinoid System of the Tumor Microenvironment
por: Kienzl, Melanie, et al.
Publicado: (2020)

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic
por: Hijmering-Kappelle, L.B.M., et al.
Publicado: (2022)

OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
por: Hijmering-Kappelle, L., et al.
Publicado: (2021)

Association of Tumor Microenvironment with Biological and Chronological Age in Head and Neck Cancer
por: van der Kamp, Martine Froukje, et al.
Publicado: (2023)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Composition and regulation of the immune microenvironment of salivary gland in Sjögren’s syndrome
por: Tan, Zhen, et al.
Publicado: (2022)

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
por: Osipov, Arsen, et al.
Publicado: (2019)

Identification of an Immune-Related Signature Predicting Survival Risk and Immune Microenvironment in Gastric Cancer
por: Dai, Shuang, et al.
Publicado: (2021)

The potential of combined mutation sequencing of plasma circulating cell‐free DNA and matched white blood cells for treatment response prediction
por: van der Leest, Paul, et al.
Publicado: (2020)

Immune Score Indicator for the Survival of Melanoma Patients Based on Tumor Microenvironment
por: Ning, Xuchao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7c5ffqi0n5hl1742nbtasfbio7